StockData

MacroGenics vs Nuvation Bio

MGNX and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGNX and NUVB compare

Nuvation Bio is the larger company, worth 9.8 times as much as MacroGenics ($1.3B against $138M).

Nuvation Bio grew revenue faster over the last twelve months (1084% versus 11.7% for MacroGenics).

MacroGenics keeps more of each dollar of sales as profit, with a net margin of −8.7% compared with −88.2% at Nuvation Bio.

MacroGenics scores higher on the StockData Score (5 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGNXNUVB
Size and price
Market cap$138M$1.3B
Share price$2.17$3.84
Change, 1 year35.6%−18.1%
Change, 5 years−88.4%−53.0%
Beta (5Y)0.451.79
Employees293298
StockData Score
Total score5 (better)4
Valuation score00
Growth score11
Performance score3 (better)1
Health score12 (better)
Dividend score00
Valuation
P/S0.8× (better)7.9×
P/B3.2× (better)5.3×
FCF yield−47.4%–
Fair value–$1.94
Margin of safety–−97.7%
Growth
Revenue growth (TTM)11.7%1084% (better)
Revenue growth, 5Y average7.3%–
Profitability
Operating margin−24.3% (better)−81.0%
Net margin−8.7% (better)−88.2%
FCF margin−39.1%–
Return on equity−32.6% (better)−47.8%
Financial health
Debt / equity–0.02
Interest coverage−2.4× (better)−5.4×
Current ratio2.968.37 (better)
Altman Z-score−4.000.09 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions76.4%66.5%
Held by insiders6.2%24.6%
Insider net buying, 12 months−$129K (better)−$4.5M
Superinvestors holding–2
Short interest, % of float8.3%23.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.